Coenzyme M

Generic Name
Coenzyme M
Brand Names
Uromitexan
Drug Type
Small Molecule
Chemical Formula
C2H6O3S2
CAS Number
3375-50-6
Unique Ingredient Identifier
VHD28S0H7F
Background

Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Indication

Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Associated Conditions
Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Associated Therapies
-

Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors

First Posted Date
2003-06-06
Last Posted Date
2019-02-15
Lead Sponsor
Children's Oncology Group
Target Recruit Count
38
Registration Number
NCT00061893
Locations
🇺🇸

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

🇺🇸

Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

🇺🇸

Edwards Comprehensive Cancer Center at Cabell Huntington Hospital, Huntington, West Virginia, United States

and more 98 locations

Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung Cancer

Phase 3
Completed
Conditions
First Posted Date
2003-04-16
Last Posted Date
2013-12-19
Lead Sponsor
Medical Research Council
Target Recruit Count
400
Registration Number
NCT00002822
Locations
🇬🇧

Medical Research Council Clinical Trials Unit, London, England, United Kingdom

Stem Cell Transplant to Treat Patients With Systemic Sclerosis

Phase 1
Completed
Conditions
First Posted Date
2003-04-09
Last Posted Date
2020-01-18
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
24
Registration Number
NCT00058578
Locations
🇺🇸

The Methodist Hospital, Houston, Texas, United States

Anti-Human CD45 Monoclonal Antibodies in Patients With Advanced Leukemia Prior to Allogeneic Stem Cell Transplantation

First Posted Date
2003-03-28
Last Posted Date
2020-01-18
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
6
Registration Number
NCT00057005
Locations
🇺🇸

The Methodist Hospital, Houston, Texas, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Phase 2
Completed
Conditions
First Posted Date
2003-01-27
Last Posted Date
2010-06-11
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
36
Registration Number
NCT00006260
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer

First Posted Date
2003-01-27
Last Posted Date
2015-08-26
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
33
Registration Number
NCT00002854
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2014-08-01
Lead Sponsor
Children's Oncology Group
Target Recruit Count
69
Registration Number
NCT00002941
Locations
🇺🇸

All Children's Hospital, St. Petersburg, Florida, United States

🇺🇸

Naval Medical Center, Portsmouth, Portsmouth, Virginia, United States

🇺🇸

Children's Hospital Central California, Madera, California, United States

and more 231 locations

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

First Posted Date
2003-01-27
Last Posted Date
2013-06-04
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
27
Registration Number
NCT00006373
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

First Posted Date
2003-01-27
Last Posted Date
2019-08-07
Lead Sponsor
Children's Oncology Group
Target Recruit Count
378
Registration Number
NCT00027846
Locations
🇺🇸

Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

🇺🇸

Advocate Christ Medical Center, Oak Lawn, Illinois, United States

and more 161 locations
© Copyright 2024. All Rights Reserved by MedPath